QV Bioelectronics was pleased to attend LSI USA 2026 in Dana Point, California, one of the leading global gatherings for emerging medtech companies, investors, and strategic partners.
During the conference, CEO Carl Daintree presented on QV Bioelectronics’ progress as the company advances towards first-in-human clinical trials. His presentation highlighted the development of GRACE, and exciting preclinical safety and efficacy data generated to date.
Held in Dana Point, the conference brought together a select group of innovators and decision-makers, providing an ideal setting for focused conversations and long-term partnership building.
QV Bioelectronics looks forward to continuing discussions initiated at LSI USA and accelerating the development of its technology towards clinical use.